AbangeLabsCEE HTA bodies like Poland's AOTMiT face a dual challenge: aligning domestic benefit-assessment methodology with EU JCA evidence standards for ITC & NMA while preserving reimbursement integrity. A practical playbook for market-access teams.
https://www.mattheneus.com/editorial/aotmit-poland-itc-nma-eu-jca-evidence-standards-cee-market-access-playbook-2026-03-27
#HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
https://www.mattheneus.com/editorial/aotmit-poland-itc-nma-eu-jca-evidence-standards-cee-market-access-playbook-2026-03-27
#HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
AOTMiT and the EU JCA Era: How Central and Eastern European HTA Bodies Are Operationalising ITC and NMA Evidence Standards
As EU JCA joint clinical assessments move from pilot to routine in 2025–2026, Central and Eastern European HTA bodies face a dual challenge: satisfying the HTA Coordination Group's evidence expectations for indirect treatment comparisons (ITC) and network meta-analysis (NMA) while maintaining the integrity of domestic reimbursement processes.